Quantessence Capital’s BioNTech BNTX Stock Holding History

Quantessence Capital’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-9,679	Closed	-$955K	–	39
2025 Q3	$955K	Buy	+9,679	New	+$1.03M	0.3%	73

Other funds holding BNTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Quantessence Capital's BNTX Position: Q4 2025 in Review

Quantessence Capital sold out of BioNTech (BNTX) in Q4 2025, closing a stake of 9,679 shares — an estimated $955K sold.

Quantessence Capital first reported a position in BNTX in Q3 2025 and held it in 1 quarter. The position peaked at $955K in Q3 2025. 284 funds tracked by Wall St. Rank hold BNTX as of Q4 2025.

Quantessence Capital reported no remaining BioNTech position as of Q4 2025 after selling out during the quarter.
Quantessence Capital sold 9,679 BioNTech shares in Q4 2025, an estimated $955K.
Quantessence Capital first reported a position in BioNTech in Q3 2025 and held it in 1 quarter.
Quantessence Capital's BioNTech position peaked at $955K in Q3 2025.
284 funds tracked by Wall St. Rank held BioNTech as of Q4 2025.

Based on Quantessence Capital's 13F filing for Q4 2025, filed 17 Feb 2026.